skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples

Factors influencing adverse events following COVID-19 vaccination

Villanueva, Paola ; McDonald, Ellie ; Croda, Julio ; Croda, Mariana Garcia ; Dalcolmo, Margareth ; Dos Santos, Glauce ; Jardim, Bruno ; Lacerda, Marcus ; Lynn, David J ; Marshall, Helen ; Oliveira, Roberto D ; Rocha, Jorge ; Sawka, Alice ; Val, Fernando ; Pittet, Laure F ; Messina, Nicole L ; Curtis, Nigel

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2323853-2323853 [Periódico revisado por pares]

United States: Taylor & Francis

Texto completo disponível

Citações Citado por
  • Título:
    Factors influencing adverse events following COVID-19 vaccination
  • Autor: Villanueva, Paola ; McDonald, Ellie ; Croda, Julio ; Croda, Mariana Garcia ; Dalcolmo, Margareth ; Dos Santos, Glauce ; Jardim, Bruno ; Lacerda, Marcus ; Lynn, David J ; Marshall, Helen ; Oliveira, Roberto D ; Rocha, Jorge ; Sawka, Alice ; Val, Fernando ; Pittet, Laure F ; Messina, Nicole L ; Curtis, Nigel
  • Assuntos: adverse events ; antibody responses ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Cohort Studies ; Coronavirus ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccine ; COVID-19 Vaccines - adverse effects ; Female ; Humans ; Vaccination - adverse effects
  • É parte de: Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2323853-2323853
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    Joint senior coauthors.
  • Descrição: Various novel platform technologies have been used for the development of COVID-19 vaccines. In this nested cohort study among healthcare workers in Australia and Brazil who received three different COVID-19-specific vaccines, we (a) evaluated the incidence of adverse events following immunization (AEFI); (b) compared AEFI by vaccine type, dose and country; (c) identified factors influencing the incidence of AEFI; and (d) assessed the association between reactogenicity and vaccine anti-spike IgG antibody responses. Of 1302 participants who received homologous 2-dose regimens of ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac), 1219 (94%) completed vaccine reaction questionnaires. Following the first vaccine dose, the incidence of any systemic reaction was higher in ChAdOx1-S recipients (374/806, 46%) compared with BNT162b2 (55/151, 36%;  = 0.02) or CoronaVac (26/262, 10%;  < 0.001) recipients. After the second vaccine dose, the incidence of any systemic reaction was higher in BNT162b2 recipients (66/151, 44%) compared with ChAdOx1-S (164/806, 20%;  < 0.001) or CoronaVac (23/262, 9%;  < 0.001) recipients. AEFI risk was higher in younger participants, females, participants in Australia, and varied by vaccine type and dose. Prior COVID-19 did not impact the risk of AEFI. Participants in Australia compared with Brazil reported a higher incidence of any local reaction (170/231, 74% vs 222/726, 31%,  < 0.001) and any systemic reaction (171/231, 74% vs 328/726, 45%,  < 0.001), regardless of vaccine type. Following a primary course of ChAdOx1-S or CoronaVac vaccination, participants who did not report AEFI seroconverted at a similar rate to those who reported local or systemic reactions. In conclusion, we found that the incidence of AEFI was influenced by participant age and COVID-19 vaccine type, and differed between participants in Australia and Brazil.
  • Editor: United States: Taylor & Francis
  • Idioma: Inglês
Links
Voltar para lista de resultados
Resultado  1 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.